FOSTER CITY, CA--(MARKET WIRE)--Jul 25, 2008 -- SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN - News) today announced that it plans to report results for the second quarter ended June 30, 2008 and host a conference call on Tuesday, July 29, 2008.

Management will review operating results for the second quarter 2008 and give a business update. The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone's website at www.sciclone.com prior the commencement of the call.

 
DATE:       Tuesday, July 29, 2008
TIME:       11:00 a.m. ET (8:00 a.m. PT)
WEBCAST:    Live call and replay accessible at http://www.sciclone.com
LIVE CALL:  877-675-4750  (U.S./Canada)
            719-325-4890  (International)
REPLAY:     888-203-1112  (U.S./Canada)
            719-457-0820  (International)
            Passcode: 4199761
            (Replay available from Tuesday, July 29, 2008 at 2:00 p.m. ET
             until 11:59 p.m. on Monday, August 25, 2008)

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in a late-stage clinical trial for the treatment of hepatitis C, and successfully completed a phase 2 clinical trial in malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC Bead(TM). For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit www.sciclone.com.

     Corporate Contact:
     Ana Kapor
     SciClone Pharmaceuticals, Inc.
     Email Contact
     650.358.3437